Active, Not Recruiting
A Study to Investigate the Effectiveness of an Education Support Program on Medication Adherence in Italian Real Life Rheumatoid Arthritis (RA) Patients Treated With Subcutaneous (SC) Abatacept - IM101-645
Updated: 4 January, 2022 | ClinicalTrials.gov
Print Friendly Summary
Trial Details
Gender(s)
Age Range
Active, Not Recruiting
Treatment Options
Inclusion Criteria: - Informed consent to participate in the study signed by the patient - Age ≥ 18 years at the date of consent subscription - Diagnosis of active Rheumatoid Arthritis moderate to severe as per the 1987 American College of Rheumatology (ACR) criteria/2010 ACR/ European League Against Rheumatism (EULAR) RA Classification Criteria - Naïve of abatacept - Initiated with abatacept SC either as 1st or 2nd line biologic treatment after inadequate response to previous therapy with one or more DMARDs according to Summary of Product Characteristics (SmPC) locally approved Exclusion Criteria: - Participating in clinical trial or other non-interventional studies, excluding registries - Inability to read and write - Any condition that in the investigator's opinion might jeopardize the follow-up and the data collection for the entire study observation period (24 months)
We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information
